Filip Janku Buys 6,000 Shares of Monte Rosa Therapeutics
Filip Janku, CMO of Monte Rosa Therapeutics, purchased 6,000 shares on June 23, 2026.
Key Points
- Filip Janku, Chief Medical Officer at Monte Rosa Therapeutics, bought 6,000 shares at $7.56 each, totaling $45,360 on June 23, 2026.
- Monte Rosa Therapeutics, trading at $20.85 on Friday, has a market cap of $1.58 billion and a forward P/E of -10.3.
- Analysts maintain a strong buy consensus for Monte Rosa with a mean price target of $32.33, based on 6 opinions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Filip Janku, the Chief Medical Officer of Monte Rosa Therapeutics, Inc., recently purchased 6,000 shares of the company. The transaction, which took place on June 23, 2026, was at an average price of $7.56 per share, amounting to a total value of $45,360. This transaction was not part of a pre-scheduled trading plan, indicating a direct decision by Janku to increase his stake in the company.
Other Institutional Activity in Monte Rosa Therapeutics
Monte Rosa Therapeutics has seen varied interest from institutional investors. Price T Rowe Associates Inc. increased its holdings by 1,601,284 shares, bringing its total to 6,720,188 shares valued at approximately $110.5 million, marking a 31.3% increase. Versant Venture Management, LLC added 1,978,873 shares, totaling 6,361,560 shares worth about $104.6 million, reflecting a 45.2% increase. BlackRock, Inc. also raised its stake by 1,456,523 shares, ending with 5,637,684 shares valued at $92.7 million, a 34.8% increase.
Monte Rosa Therapeutics, Inc. Stock Up 61.9%
Shares of NasdaqGS:GLUE traded near $20.85 on Friday. Monte Rosa Therapeutics has a market capitalization of approximately $1.58 billion. The company isn't currently profitable, as indicated by its forward P/E ratio of -10.3. With a beta of 1.602, the stock has experienced a 52-week range between $4.12 and $25.77. The 50-day moving average stands at $18.68, while the 200-day moving average is $15.84. Monte Rosa maintains a strong liquidity position with a current ratio of 9.54 and a quick ratio of 9.44, coupled with a debt-to-equity ratio of 7.49.
$GLUE stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Monte Rosa Therapeutics reported revenue of $42.95 million, although it experienced a revenue decline of 95%. The company is not currently profitable, with a net margin of 0% and a return on equity of -32.62%. The next earnings report is scheduled for August 6, 2026.
Insider Buying and Selling at Monte Rosa Therapeutics, Inc.
In addition to Filip Janku's recent purchase, other insiders have been active. Jennifer Champoux, the Chief Operating Officer, bought 2,175 shares at $3.98 each on June 23, 2026. Meanwhile, Sharon Townson, the Chief Scientific Officer, sold 3,000 shares on the same day. These transactions were not part of any planned trading arrangements.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on Monte Rosa Therapeutics. On May 11, 2026, JP Morgan maintained its 'buy' rating with a price target of $31. Guggenheim and Wells Fargo also upheld their 'buy' ratings earlier in the year, with targets of $30 and $29, respectively. The consensus among analysts is a strong buy, with an average target price of $32.33 based on six opinions.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing small molecule precision medicines. The company works on creating molecular glue degraders to treat various diseases, including MYC-driven tumors and inflammatory diseases. The firm, led by CEO Dr. Markus Warmuth, collaborates with major partners like F. Hoffmann-La Roche and Novartis.
Bottom Line
Filip Janku's recent purchase of Monte Rosa Therapeutics shares reflects a personal investment decision by a key executive. The company's stock has seen significant institutional interest, with several investors increasing their stakes. Analysts continue to view the stock favorably, maintaining a strong buy consensus. As always, remember that insider transactions and institutional filings offer a backward-looking insight into the company's stock activities.
Get Monte Rosa Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GLUE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.